$10 MILLION INVESTMENT IN VIVE CROP PROTECTION

August 27, 2019 — Vive Crop Protection is pleased to announce the closing of its $10 million financing from existing and new investors, including Middleland Capital and the Business Development Bank of Canada’s (“BDC”) Cleantech Practice. This capital will support commercialization of three new crop protection products and continued field development of Vive’s deep pipeline.

Darren Anderson, CEO of Vive Crop Protection says, “Thanks to the leadership of Vive Executive Chairman Keith Thomas, we were able to close this financing round led by investors who understand the value of Vive’s technology.” MORE>>

PROMIS NEUROSCIENCES ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS

TORONTO, ON. and CAMBRIDGE, MA. – July 24, 2019 – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases,  today announced the voting results of the Corporation’s annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario, Canada (the “Meeting”).  MORE>>

PROMIS NEUROSCIENCES HIGHLIGHTS DATA FOR PMN310 AT AAIC 2019

TORONTO, Ontario and CAMBRIDGE, Mass. —July 18, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data today for its lead clinical candidate, PMN310 for Alzheimer’s disease, at the annual Alzheimer’s Association International Conference® (AAIC) in Los Angeles. MORE>>

PROMIS NEUROSCIENCES TO PRESENT DATA AT 2019 ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE

TORONTO, Ontario and CAMBRIDGE, Mass. —July 10, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give an oral presentation on its lead clinical candidate, PMN310 for Alzheimer’s disease, at the annual Alzheimer’s Association International Conference® (AAIC), which occurs July 14-18.  A second poster presentation focuses on the behavior of misfolded TDP43 involved in the development of neurological disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. MORE>>

PROMIS NEUROSCIENCES’ DATA FOR ALZHEIMER’S DISEASE CLINICAL CANDIDATE PMN310 PUBLISHED IN SCIENTIFIC REPORTS

TORONTO, Ontario and CAMBRIDGE, Mass. —July 9, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that supporting data for PMN310, its lead antibody candidate for Alzheimer’s disease (AD), have been published in Scientific Reports, a journal of the Nature Research family. The open-access study is available on the Scientific Reports website  using the following direct link: https://rdcu.be/bJeLB MORE>>